Pieris Pharmaceuticals (NASDAQ:PIRS) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Down 15.7 %

PIRS opened at $13.60 on Thursday. The business has a fifty day simple moving average of $15.72 and a 200-day simple moving average of $14.82. The firm has a market cap of $17.95 million, a PE ratio of -1.12 and a beta of 0.61. Pieris Pharmaceuticals has a fifty-two week low of $6.20 and a fifty-two week high of $22.32.

Institutional Trading of Pieris Pharmaceuticals

An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. acquired a new position in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned approximately 1.21% of Pieris Pharmaceuticals at the end of the most recent quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.